Show simple item record

dc.contributor.authorJordan, S
dc.contributor.authorSteer, C
dc.contributor.authorDeFazio, A
dc.contributor.authorQuinn, M
dc.contributor.authorObermair, A
dc.contributor.authorFriedlander, M
dc.contributor.authorFrancis, J
dc.contributor.authorO'Brien, S
dc.contributor.authorGoss, G
dc.contributor.authorWyld, D
dc.contributor.authorWebb, P
dc.identifierpii: S0090-8258(13)00078-4
dc.identifier.citationJordan, S., Steer, C., DeFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D. & Webb, P. (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study. GYNECOLOGIC ONCOLOGY, 129 (2), pp.310-317.
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractOBJECTIVE: Ovarian cancer five-year survival is poor at <40%. In the absence of effective screening or new treatments, ensuring all women receive optimal treatment is one avenue to improve survival. There is little population-based information regarding the primary chemotherapy treatment that women with epithelial ovarian cancer receive. This information is essential to identify potential gaps in care. METHODS: Cancer registries identified all women diagnosed with invasive epithelial ovarian cancer in Australia in 2005 (n=1192). Histopathology, chemotherapy and comorbidity information was abstracted from medical records. Multivariable logistic regression was used to identify factors associated with chemotherapy commencement, regimen, and completion. RESULTS: Women >70 years (p<0.0001), those with high-grade, stage IA/IB cancers (vs. stages IC-IV, p=0.003) and those with mucinous cancers (p=0.0002) were less likely to start chemotherapy. Most treated women received platinum-based drugs (97%), but only 68% received combination carboplatin-paclitaxel and only half completed six cycles without treatment modification/delay. Approximately 19% received single-agent carboplatin: mostly those aged >70 (p<0.0001) and/or with co-morbidities (p<0.0001). Age was the strongest predictor of completing six cycles of combination therapy. CONCLUSIONS: For specific patient groups, particularly older women, there is notable variation from standard treatment. Understanding how treatment variations affect survival and determining optimal regimens for these groups are research priorities.
dc.subjectChemotherapy; Obstetrics and Gynaecology; Cancer and Related Disorders; Women's Health
dc.titlePatterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - A population-based study
dc.typeJournal Article
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentObstetrics And Gynaecology Royal Women'S Hospital/Mercy
melbourne.source.titleGYNECOLOGIC ONCOLOGY
melbourne.contributor.authorQUINN, MICHAEL
melbourne.identifier.fundernameidNHMRC, 400281
melbourne.identifier.fundernameidNHMRC, 400413
melbourne.fieldofresearch321105 Chemotherapy
melbourne.fieldofresearch321502 Obstetrics and gynaecology
melbourne.seocode200199 Clinical health not elsewhere classified
melbourne.seocode200509 Women's and maternal health
melbourne.accessrightsThis item is currently not available from this repository

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record